Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $147.3 million.

  • Silence Therapeutics' Cash & Current Investments rose 52.01% to $122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $664.5 million, marking a year-over-year increase of 42.02%. This contributed to the annual value of $147.3 million for FY2024, which is 39.31% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Cash & Current Investments is $147.3 million, which was up 39.31% from $105.8 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Cash & Current Investments registered a high of $147.3 million during FY2024, and its lowest value of $37.2 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $105.8 million (2023), whereas its average is $107.0 million.
  • In the last 5 years, Silence Therapeutics' Cash & Current Investments soared by 172.24% in 2021 and then crashed by 32.95% in 2022.
  • Over the past 5 years, Silence Therapeutics' Cash & Current Investments (Yearly) stood at $37.2 million in 2020, then skyrocketed by 172.24% to $101.2 million in 2021, then plummeted by 32.95% to $67.8 million in 2022, then soared by 55.89% to $105.8 million in 2023, then skyrocketed by 39.31% to $147.3 million in 2024.